After Jefferies and Mizuho Securities gave Supernus Pharmaceuticals (NASDAQ: SUPN) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Matthew Lillis reiterated a Buy rating on Supernus Pharmaceuticals today and set a price target of $60. The company’s shares closed yesterday at $36.96.
Lillis noted:
“We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets SPN-810 and SPN-812 and the bipolar indication opportunity for Oxtellar XR.”
According to TipRanks.com, Lillis is a 3-star analyst with an average return of 4.6% and a 53.3% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Evofem Biosciences Inc, and Amag Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $61.50 average price target, implying a 66.4% upside from current levels. In a report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $63 price target.
See today’s analyst top recommended stocks >>
Supernus Pharmaceuticals’ market cap is currently $1.93B and has a P/E ratio of 18.01. The company has a Price to Book ratio of 4.27.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SUPN in relation to earlier this year. Last month, John Siebert, a Director at SUPN bought 10,000 shares for a total of $91,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
